Authors
Loading...
Randomized trial evaluates PepGAT's impact on C. albicans, suggesting new antifungal alternatives.
Gomes et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: